Literature DB >> 4950407

The recovery of immune responsiveness after treatment with cyclophosphamide.

J Marbrook, B C Baguley.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4950407     DOI: 10.1159/000230572

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


× No keyword cloud information.
  8 in total

1.  ICP0 is required for efficient reactivation of herpes simplex virus type 1 from neuronal latency.

Authors:  W P Halford; P A Schaffer
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  A comparison of thymus dependent and thymus independent antibody responses made by different numbers and populations of immunocompetent cells.

Authors:  I E Addison
Journal:  Br J Exp Pathol       Date:  1974-04

3.  Optimized viral dose and transient immunosuppression enable herpes simplex virus ICP0-null mutants To establish wild-type levels of latency in vivo.

Authors:  W P Halford; P A Schaffer
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

4.  Relationship between delayed hypersensitivity response and acquired cell-mediated immunity in C57BL/6J mice infected with Leishmania donovani.

Authors:  J R Fahey; R Herman
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

5.  Mouse model for abortive rabies infection of the central nervous system.

Authors:  J S Smith
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

6.  Correlation between in vivo and in vitro studies of modulation of resistance to experimental Candida albicans infection by cyclophosphamide in mice.

Authors:  F Bistoni; M Baccarini; E Blasi; P Marconi; P Puccetti; E Garaci
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

7.  Effects of cyclophosphamide on murine candidiasis.

Authors:  S A Moser; J E Domer
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

8.  Recovery of immune responsiveness to rabies vaccine after treatment of mice with cyclophosphamide.

Authors:  G S Turner
Journal:  Arch Virol       Date:  1979       Impact factor: 2.574

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.